COVID-19 is boosting microfluidics’ revenues as well as point-of-care technology adoption and will have a durable impact on the industry
- Understand short- and long-term impact of the COVID-19 pandemic on the industry along with new related opportunities and who the main winners will be
- Learn more about eight application areas where things are hot currently
- Understand the competitive environment with detailed market shares per segment for the first time in this report
- Discover a detailed cost analysis regarding manufacturing line set-up and different types of microfluidic device/product manufacturing
- Benefit from a more detailed materials analysis this year, including glass and silicon wafer and raw polymer market sizes and forecasts
- Enter the world of microneedles with a dedicated chapter describing market and technology trends regarding this area
- Enjoy in-depth manufacturing process descriptions and comparison
- COVID-19 impact
- Market segmentation, data and forecasts 2019-2025, by devices and products, in units and dollars, including material mix and wafer info
- Detailed explanation of current and future market trends, covering many applications of microfluidics
- Fundraising and M&A analysis help understanding the hot spots
- Market shares at different levels of the supply chain, including fabs and integrators, with comparison to last year, explaining the dynamics
- Materials, manufacturing and other technology trends, including alternatives to PCR, and roadmaps
- Cost analysis for microfluidic cartridge manufacturing and inhouse vs outsourcing analysis
- Detailed description of every market segment including market and technology trends, and key players and product examples
This new Yole Développement report provides a complete analysis of microfluidic device/product applications, markets, and technologies:
- Analysis of COVID-19 short- and long-term impact on applications, players, and new opportunities
- New major trends and evolution in the microfluidic industry markets, applications, and business models
- Presentation of the hot spots where things are moving, along with future high-potential applications
- Analysis of strategic moves since 2019 including mergers and acquisitions and fundraising
- Understanding of the competitive environment with an overview of key players and products per segment, and evolution of microfluidic integrators’ market shares per segment, and of foundries’ market shares
- Updated market data and forecast up to 2025, in value and units for microfluidic devices and products, with insights about the materials market including polymer, glass wafers and silicon wafers
- Supply chain description and analysis
- Cost analysis for the manufacturing of microfluidic devices with different materials and processes, and for the establishment of a manufacturing line
- Latest technology trends including materials, manufacturing, biology, detection methods and multi-modal platforms
Table of Contents
Definitions, table of contents, methodology 2
Executive Summary 20
Impact of the COVID-19 pandemic 71
- Impact of the COVID-19 pandemic on the overall healthcare market
- Matrix: types of tests for COVID-19
- What’s the impact on the overall microfluidic market?
- Estimated impact of the COVID-19 pandemic on each segment
- Main winners in numbers, and examples of tests
- SARS-CoV-2 point-of-care molecular diagnostic tests
- Start-up companies put important resources in COVID-19 tests development
- Microfluidic companies funding related to the pandemic
- Mid- and long-term opportunities for POC test makers
Market forecasts 92
- Microfluidic functions and applications, market segmentation
- Microfluidic devices and products market forecasts, in volume and in dollars
- Segment dynamics
- How the value is spread across the supply chain
- What we got right/wrong and why
- Material mix analysis
- Wafer and raw material forecasts
Market trends 120
- Microfluidic devices complexity vs. applications
- Most promising applications have not reached their full potential yet
- Evolution of business models
- The eight main areas where we see things moving over the past year
- In-house vs. outsourced production
- Fundraising analysis
- M&A analysis
Focus on microneedles 158
- Types of microneedles and applications
- Trends, players and products examples
Market shares and supply chain 168
- List of microfluidic integrators, by material
- Microfluidic products market – Top 15 integrators
- Market shares per segment
- Microfluidic fabs: mapping, geographical location, ranking, analysis
- Semiconductor players still show high interest
Technology trends 194
- Materials: description, comparison, hybrid integration, bonding
- Manufacturing processes: overview, description, comparison, trends
- Surface modification
- Graphene: a new material for biomedical sensors?
- Towards molecular electronics
- Detection methods overview; type of test vs. type of detection
- Focus on molecular diagnostics: PCR vs. alternative methods, and roadmap for molecular diagnostics methods
Cost analysis 237
- Complexity of microfluidic cartridges
- Cost modelling
- In-house vs. outsourced manufacturing: pros and cons
- Investment in a production line: semi-auto vs. auto
- Process flow examples
- Cost analysis: equipment, cartridge parts, materials, design
- Summary recommendations
- Value chain – estimations and examples
- Gross margin on microfluidic products
Report conclusion 267
- Market segment descriptions, including: one-slide summary, examples of key players and products, main market and technology trends, technical and behavioral requirements
- Emerging applications
- Who’s working with whom?
- Other technology trends
Yole Développement presentation 285
THE COVID-19 PANDEMIC HAS A STRONG SHORT-TERM IMPACT ON THE DIAGNOSTICS INDUSTRY AND WILL ALSO DURABLY RESHAPE IT
Following the advent of COVID-19 in early 2020, our society has encountered an unprecedented health and economic situation. Many countries around the world have had either partial or complete lockdowns for different durations. It’s been more than six months and the situation is far from returning to normal, although life continues.
In that context, and in order to understand the virus and control its spread, there is a continued strong demand for respiratory diagnostic tests. The world also needs research tools to study the virus’ properties and mutations and help develop treatments or vaccines. This strong demand has pushed many diagnostics players to repurpose existing systems to detect the virus or associated antibodies. On the other hand their usual activity has been offset by lab closures and reluctance of patients to undergo their usual healthcare consultations. Microfluidic technologies have been used in various solutions. These include molecular diagnostics, immunoassays, rapid point-of-care tests and high-throughput solutions for centralized labs. There was an initial shortage of tests and it took time to develop appropriate solutions and to scale production lines. Numerous companies of all sizes including Abbott, Cepheid and bioMérieux have therefore had the opportunity to place many instruments at new customers’ places because they were among the first to offer COVID-19 tests. They sold many of these tests, resulting in a spike in revenues for Q1 and even more for Q2 2020. This dynamic seems on track for Q3, Q4 and at least to early 2021 as the pandemic continues. A second wave is starting to strike some countries, and healthcare organizations are now testing many more people than several months ago. However, this is not a one-shot rise in revenue that will come back to normal soon. Once the pandemic is over, these instruments will remain in place and be used for other tests that these companies offer. This will take their consumables sales to a higher level than before the pandemic.
In this report, Yole Développement (Yole) explains COVID-19’s impact on the microfluidics industry. The report reveals who the main winners will be and why. Analysts also describe how the situation opens up significant new opportunities in areas such as travel and workplaces – with rapid passenger or visitor screening – that represent billions of potential tests every year needed to help restart the world’s economy. Moreover, governments and society have realized the importance of such diagnostic tests. They will surely support their continued development to be ready in case of another future pandemic. The diagnostics industry may therefore make the best of this bad situation and turn it in a real springboard. The pandemic could eventually push point-of-care testing to where it belongs, a true killer application of microfluidics.
THE MICROFLUIDICS INDUSTRY MATURES
Wherever we look, in most applications, we’re in a period where volumes are ramping up rapidly. This is a sign of the technology and the business models maturing. The sale of consumables is still the main model in microfluidics, however companies are finding more convenient solutions for their customers. For example, different companies are developing consumables for a common instrument so that customers only have to purchase a single instrument to run many types of test.
Reagent rental options also diversify and take various forms, always to facilitate adoption. Indeed, successful commercialization of microfluidic products and devices is improving, but still not easy. Besides point-of-care testing, the market is driven by tools for pharmaceutical and life science research. These include DNA sequencing, other genomics and proteomics tools, and much more. Moreover, new applications include liquid lenses, which enable miniaturized and enhanced optical actuation. These are now reaching commercialization and show tremendous potential for industrial and consumer applications. It confirms once again that microfluidic technologies are not limited to life sciences and healthcare.
In this report, Yole’s analysts present microfluidics’ eight main hot areas. Furthermore, they detail how the microfluidic products market will grow from $11.2B in 2019 at a Compound Annual Growth Rate (CAGR2019-2025) of 14% to reach $24.5B by 2025. They describe the dynamics for each application. The report includes the market size for microfluidic device manufacturers and for the different materials – polymer, glass and silicon – used to manufacture microfluidic chips. Indeed, polymers are the most widely used material for manufacturing microfluidic devices, used in 92% of them, but only accounts for 34% of the market value. Glass and silicon devices, used in high-end applications, are much more expensive. In particular, silicon is increasingly used for on-chip sensing purposes and will take share in the coming years. Therefore, Yole provides an understanding of the opportunities in terms of glass and silicon wafers in the microfluidics field.
DIAGNOSTICS GIANTS USUALLY DON’T OUTSOURCE THEIR PRODUCTION. CAN RECENT MICROFLUIDIC FAB ACQUISITIONS CHANGE THE SITUATION?
There are now thousands of microfluidic companies. Most of them use the services of specialized microfluidic device contract manufacturers, so-called “fabs”, to manufacture the chips their need to implement their assays on.
However, ten giant companies, including Illumina, bioMérieux, Abbott and Cepheid, hold almost 75% of the microfluidic product market. Most of these ten leaders manufacture their microfluidic devices – up to tens of millions per year each – in their own factories. Meanwhile, small and medium companies are struggling to make it to the next step. Most of them remain well below million-unit volumes of each product annually. When a small company finally starts to grow, it gets acquired by giant companies that often bring manufacturing in-house. As a consequence, fabs don’t have the chance to mass-produce microfluidic devices and have wondered how to attract blue-chip players for many years.
The response could come from other industries, where large players recently shifted up a gear. Companies like Teledyne, Schott, and IDEX have done major fab acquisitions with Micralyne, MiniFAB and thinXXS. This brings all these fabs’ know-how into the hands of major companies used to working with industry leaders. In the meantime, important players from the semiconductor industry like X-FAB proceed to make significant investments in microfluidics.
More than ever, microfluidics represents a tremendous potential for classic semiconductor players. They see a significant growth opportunity in the medical market. But are these investments enough to shift life science and diagnostics giants’ manufacturing strategies? It is certainly worth a try, but more investment is needed.
In this report, Yole’s analysts provide market shares of integrators on eight segments of the microfluidics market. The report also includes market shares of microfluidic fabs, giving readers a comprehensive understanding of the competitive environment within this industry. An analysis of recent industry moves, including fundraising and mergers and acquisitions (M&A), is also discussed.
10X Genomics, Abaxis (Zoetis), Abbott, Affymetrix (Thermo Fisher), Agilent Technologies, binx health, Axxicon, Balda AG (Stevanato Group), BD, Berkeley Lights, BGI, Biocartis, BioFire Diagnostics (bioMérieux), bioMérieux, Bionano Genomics, Bio-Rad, BioSurfit, Boehringer Ingelheim, Bosch Vivalytic, PerkinElmer, CapitalBio, Cellenion (Scienion, CELLINK), Cepheid (Danaher), Charles River, Corning, Cue Health, Curetis (OpGen), Curiosity Diagnostics (Scope Fluidics), Cytena (CELLINK), Denz Bio-Medical, DiaSorin Molecular, DNA electronics (DNAe), DNA Nudge, Elveflow (Elvesys), ENPLAS, EVG (EV Group), Fluidigm, Fluigent, Fluxergy, Formulatrix (Qiagen), Genalyte, GenapSys, GeneDisc (Pall Corporation), GenePOC (Meridian Bioscience), GenMark Diagnostics, Gyros Protein Technologies (Mesa Labs), HemoCue (Radiometer, Danaher), Hicomp, Hochuen, IBM, Illumina, imec, IMT AG, IMT MEMS, InSilixa, Intel, Invenios (Corning), Kloé, LabCyte (Beckman Coulter, Danaher), LexaGene, LioniX, Little Things Factory (Plan Optik), L’Oréal, Luminex Corporation, LumiraDx, MBio Diagnostics, MedSpray, Mesa Biotech, MGI (BGI), Micralyne (Teledyne), Microfluidic ChipShop, MicroLiquid, Micronit, Minicare (Siemens), MiniFAB (Schott), Mobidiag, Nabsys, Nanomedical Diagnostics (Cardea), NanoString Technologies, NeuMoDx (Qiagen), Nypro (Jabil), Omniome, Oxford Nanopore Technologies, Pacific Biosciences, Philips Innovation Services, Qiagen, Qorvo Biotechnologies, Quanterix, QuantuMDx, Quidel Corporation, Rheonix, Roche, Rogue Valley Microdevices, Roswell Biotechnologies, Samsung, Sanwa Biotech, Sartorius, Schott, Schlumberger, Sense Biodetection, Siemens Healthineers, Silex Microsystems, SkyWater Technology Foundry, SphereFluidics, SpinChip Diagnostics, SpinDiag, Stat-Dx (Qiagen), Stilla Technologies, STMicroelectronics, Stratec Consumables, Surfix (LioniX), T2 Biosystems, Talis Biomedical, Tangen Biosciences, Technicolor Precision Biodevices, Tecnisco, TearLab (AccelMed Partners), Teledyne Dalsa, Thermo Fisher Scientific, thinXXS (IDEX), Truvian Sciences, TSMC, Two Pore Guys (Ontera), Varioptic (Invenios, Corning), Veredus Laboratories, X-FAB, z-microsystems, and more…